The role of complement in the antiphospholipid syndrome: A novel mechanism for pregnancy morbidity

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 1, 2012, Pages 66-69

  Samarkos, Michael ^a   Mylona, Eleni ^a   Kapsimali, Violeta ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antiphospholipid syndrome; Complement; Fetal loss; Thrombosis

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; COMPLEMENT REGULATORY PROTEIN; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; PHOSPHOLIPID ANTIBODY; REGULATOR PROTEIN; SERINE PROTEINASE INHIBITOR; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; DRUG MECHANISM; FETOPLACENTAL UNIT; FETUS WASTAGE; GENE MUTATION; HUMAN; INFLAMMATION; MEDICAL LITERATURE; MORBIDITY; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; THROMBOGENESIS; THROMBOSIS;

ADULT; ANIMALS; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT C5A; COMPLEMENT PATHWAY, ALTERNATIVE; DISEASE MODELS, ANIMAL; FEMALE; FETAL DEATH; HUMANS; MICE; MICE, KNOCKOUT; NEUTROPHILS; PREGNANCY; RECEPTOR, ANAPHYLATOXIN C5A; THROMBOSIS;

EID: 84864114536     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.01.001     Document Type: Article

References (31)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019-1027.
3. Levine J.S., Branch D.W., Rauch J. The antiphospholipid syndrome. N Engl J Med 2002, 346:752-763.
4. Espinosa G., Cervera R., Font J., Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev 2003, 2:86-93.
5. Meroni P.L., Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr Opin Rheumatol 2001, 13:377-382.
6. Vlachoyiannopoulos P.G., Samarkos M., Sikara M., Tsiligros P. Antiphospholipid antibodies: Laboratory and pathogenetic aspects. Crit Rev Clin Lab Sci 2007, 44:271-338.
7. Xu C., Mao D., Holers V.M., Palanca B., Cheng A.M., Molina H. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 2000, 287:498-501.
8. Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211-220.
9. Pierangeli S.S., Liu X.W., Barker J.H., Anderson G., Harris E.N. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995, 74:1361-1367.
10. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003, 112:1644-1654.
11. Thurman J.M., Kraus D.M., Girardi G., Hourcade D., Kang H.J., Royer P.A., et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 2005, 42:87-97.
12. Berman J., Girardi G., Salmon J.E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005, 174:485-490.
13. Ritis K., Doumas M., Mastellos D., Micheli A., Giaglis S., Magotti P., et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006, 177:4794-4802.
14. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Meckman N., et al. Tissue factor: a link between C5a and neutrophil activation I antiphospholipid antibody-induced fetal injury. Blood 2007, 110:2423-2431.
15. Strukova S. Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis. Front Biosci 2006, 11:59-80.
16. Redecha P., Franzke C.-W., Ruf W., Mackman N., Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008, 118(10):3453-3461.
17. Kazatchkine M.D., Fearon D.T., Metcalfe D.D., Rosenberg R.D., Austen K.F. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981, 67:223-228.
18. Di Simone N., Caliandro D., Castellani R., Ferrazzani S., De Carolis S., Caruso A. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod 1999, 14:489-495.
19. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
20. Francis J., Rai R., Sebire N.J., El-Gaddal S., Fernandes M.S., Jindal P., et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006, 12:435-442.
21. Schwarzenbacher R., Zeth K., Diederichs K., Gries A., Kostner G.M., Laggner P., et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999, 18:6228-6239.
22. Noris M., Brioschi S., Caprioli J., Todeschini M., Bresin E., Porrati F., et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003, 362:1542-1547. International Registry of Recurrent and Familial HUS/TTP.
23. Kravitz M.S., Shoenfeld Y. Thrombocytopenic conditions-autoimmunity and hypercoagulability: commonalities and differences in ITP, TTP, HIT, and APS. Am J Hematol 2005, 80:232-242.
24. Salmon J.E., Heuser C., Triebwasser M., Liszewski M.K., Kavanagh D., Roumenina L., et al. Mutations in complement regulatory proteins predispose to peeclampsia: A genetic analysis of the PROMISSE cohors. PLoS Med 2011, 8(3). e1001013.
25. Oku K., Atsumi T., Bohgaki M., Amengual O., Kataoka H., Horita T., et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009, 68:1030-1035.
26. Shamonki J.M., Salmon J.E., Hyjek E., Baergen R.N. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007, 196:167.e1-167.e5.
27. Cavazzana I., Nebuloni M., Cetin I., Acaia B., Saino S., Borghi M.O., et al. Complement activation in anti-phospholipid syndrome: A clue for an inflammatory process?. J Autoimmun 2007, 28:160-164.
28. Pierangeli S.S., Girardi G., Vega-Ostertag M., Liu X., Espinola R.G., Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120-2124.
29. Romay-Penabad Z., Liu X.X., Montiel-Manzano G., Papalardo de Martinez E., Pierangeli S.S. C5a Receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann NY Acad Sci 2007, 1108:554-566.
30. Fischetti F., Durigutto P., Pellis V., Debeus A., Macor P., Bulla R., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106:2340-2346.
31. Peerschke E.I.B., Yin W., Alpert D.R., Roubey R.A.S., Salmon J.E., Ghebrehiwet B. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2009, 18(6):530-538.